Cagrilintide protocol
Cagrilintide (long-acting amylin analog). Dosing on this page comes from a published human trial or an approved product label, cited below.
How Cagrilintide works
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It acts on satiety pathways distinct from GLP-1, which is why it is studied alongside incretin agonists rather than instead of them.
Cagrilintide dosing schedule
From the phase 2 dose-finding trial, which escalated monthly across ascending arms.
| Phase | Amount | Frequency | Notes |
|---|---|---|---|
| Weeks 1–4 | 0.3 mg | Once weekly | Lowest arm, and the lead-in for higher arms. |
| Weeks 5–8 | 0.6 mg | Once weekly | |
| Weeks 9–12 | 1.2 mg | Once weekly | |
| Weeks 13–16 | 2.4 mg | Once weekly | |
| Week 17 onward | 4.5 mg | Once weekly | Highest arm studied. |
Study length: 26 weeks in the phase 2 trial.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for Cagrilintide: Not stocked by our featured supplier.
Storage and stability
Reported effects
- Gastrointestinal effects were the most common, consistent with the class.
- Injection-site reactions were reported more often than with incretin agonists.
Sourcing Cagrilintide
Our featured supplier does not stock this compound, and we are not going to point you at a vendor we have not looked at. Use the COA checklist on whoever you do buy from, and check the batch number on the certificate against the vial you receive.
